XML 32 R15.htm IDEA: XBRL DOCUMENT
v3.24.0.1

DEFERRED POLICY ACQUISITION COSTS AND INSURANCE EXPENSES | 12 Months Ended
--- | ---
Dec. 31, 2023
Deferred Policy Acquisition Costs Disclosures [Abstract] |
DEFERRED POLICY ACQUISITION COSTS AND INSURANCE EXPENSES | DEFERRED POLICY ACQUISITION COSTS AND INSURANCE EXPENSES The following tables present a rollforward of deferred policy acquisition costs by reporting segment and disaggregated by product type for the years ended December 31.
| 2023
| Aflac Japan |  | Aflac U.S. |  |
(In millions) | Cancer | Medical and Other Health | Life Insurance | Other |  | Accident | Disability | Critical Care | Hospital Indemnity | Dental/Vision | Life Insurance | Other |  | Total
Deferred policy acquisition costs: |  |  |  |  |  |  |  |  |  |  |  |  |  |
Balance, beginning of year | $ | 3,035 |  | $ | 2,161 |  | $ | 525 |  | $ | 55 |  |  | $ | 904 |  | $ | 613 |  | $ | 1,304 |  | $ | 418 |  | $ | 88 |  | $ | 135 |  | $ | 1 |  |  | $ | 9,239 |
Capitalization | 317 |  | 123 |  | 33 |  | 8 |  |  | 151 |  | 125 |  | 173 |  | 84 |  | 10 |  | 61 |  | 1 |  |  | 1,086 |
Amortization expense | (184) |  | (105) |  | (34) |  | (3) |  |  | (138) |  | (113) |  | (141) |  | (66) |  | (12) |  | (24) |  | 4 |  |  | (816) |
Foreign currency translation and other | (197) |  | (138) |  | (33) |  | (4) |  |  | 0 |  | 0 |  | 0 |  | 0 |  | 0 |  | 0 |  | (5) |  |  | (377) |
Balance, end of year | $ | 2,971 |  | $ | 2,041 |  | $ | 491 |  | $ | 56 |  |  | $ | 917 |  | $ | 625 |  | $ | 1,336 |  | $ | 436 |  | $ | 86 |  | $ | 172 |  | $ | 1 |  |  | $ | 9,132 |
Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts.
| 2022
| Aflac Japan |  | Aflac U.S. |  |
(In millions) | Cancer | Medical and Other Health | Life Insurance | Other |  | Accident | Disability | Critical Care | Hospital Indemnity | Dental/Vision | Life Insurance | Other |  | Total
Deferred policy acquisition costs: |  |  |  |  |  |  |  |  |  |  |  |  |  |
Balance, beginning of year | $ | 3,464 |  | $ | 2,372 |  | $ | 595 |  | $ | 51 |  |  | $ | 887 |  | $ | 604 |  | $ | 1,270 |  | $ | 399 |  | $ | 90 |  | $ | 115 |  | $ | 1 |  |  | $ | 9,848 |
Capitalization | 291 |  | 161 |  | 33 |  | 12 |  |  | 147 |  | 117 |  | 160 |  | 80 |  | 11 |  | 40 |  | 0 |  |  | 1,052 |
Amortization expense | (188) |  | (112) |  | (35) |  | (3) |  |  | (130) |  | (108) |  | (126) |  | (61) |  | (13) |  | (20) |  | 4 |  |  | (792) |
Foreign currency translation and other | (532) |  | (260) |  | (68) |  | (5) |  |  | 0 |  | 0 |  | 0 |  | 0 |  | 0 |  | 0 |  | (4) |  |  | (869) |
Balance, end of year | $ | 3,035 |  | $ | 2,161 |  | $ | 525 |  | $ | 55 |  |  | $ | 904 |  | $ | 613 |  | $ | 1,304 |  | $ | 418 |  | $ | 88 |  | $ | 135 |  | $ | 1 |  |  | $ | 9,239 |
Prior-year amounts have been adjusted for the adoption of accounting guidance on January 1, 2023 related to accounting for long-duration insurance contracts. Commissions deferred as a percentage of total acquisition costs deferred were 67% in 2023, compared with 68% in 2022 and 71% in 2021. The Company uses the following constant level bases to amortize deferred policy acquisition costs:
Policy Type |  | Constant-level Basis
Life Products (U.S.) |  | Face Amount
Health Products (U.S.) |  | Number of Policies in Force
Health & Life Products (Japan) |  | Units in Force
Face amount is the stated dollar amount that the policy’s beneficiaries receive upon the death of the insured. For life and health products issued in Japan, the constant-level basis used is units in force, which is a proxy for face amount and insurance in force, respectively. Future DAC amortization is impacted by persistency. There were no changes to the inputs or methods used to determine amortization amounts during 2023 and 2022. The Company updated the assumptions used to determine amortization using the same assumptions as those used for measuring the liability for future policy benefits during 2023 and 2022. The Company recognizes the effects of changes in assumptions prospectively over the remaining contract term as a revision of the future amortization pattern. See Note 1 for additional information on deferred policy acquisition costs. Personnel, compensation and benefit expenses as a percentage of insurance expenses wer e 61% in 2023, compared with 60% in 2022 and 57% in 2021. Advertising expense, which is included in insurance expenses in the consolidated statements of earnings, was as follows for the years ended December 31:
(In millions) | 2023 |  | 2022 |  | 2021
Advertising expense: |  |  |  |  |  |  |  |  |  |  |
Aflac Japan |  | $ | 58 |  |  |  |  | $ | 77 |  |  |  |  | $ | 91 |  |
Aflac U.S. |  | 130 |  |  |  |  | 127 |  |  |  |  | 138 |  |
Total advertising expense |  | $ | 188 |  |  |  |  | $ | 204 |  |  |  |  | $ | 229 |  |
Depreciation and other amortization expenses, which are included in insurance expenses in the consolidated statements of earnings, were as follows for the years ended December 31:
(In millions) | 2023 |  | 2022 |  | 2021
Depreciation expense |  | $ | 35 |  |  |  |  | $ | 40 |  |  |  |  | $ | 39 |  |
Other amortization expense |  | 4 |  |  |  |  | 5 |  |  |  |  | 6 |  |
Total depreciation and other amortization expense |  | $ | 39 |  |  |  |  | $ | 45 |  |  |  |  | $ | 45 |  |

X
- References No definition available. + Details
Name: | us-gaap_DeferredPolicyAcquisitionCostsDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for deferred policy acquisition costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 944 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//944-30/tableOfContent + Details
Name: | us-gaap_DeferredPolicyAcquisitionCostsTextBlock1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration